A Phase I/IIa, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of AP23573 [deforolimus] When Administered Orally in Patients With Refractory or Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 06 May 2014
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 07 Jun 2017 Biomarkers information updated
- 29 May 2013 Primary endpoints added as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.